ICCCHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 12 Oct 2026 — among the strongest tenth.
Consensus tells you what everyone already believes. The model scores ImmuCell Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ICCC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 July 2020 | Aegis Capital | Initiates | Buy | $14 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ICCC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, ImmuCell Corp. returned +64.0% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 5% of US stocks
Cheaper than 41% of US stocks
Cheaper than 33% of US stocks
Cheaper than 27% of US stocks
Higher than 56% of US stocks
Higher than 92% of US stocks
Higher than 40% of US stocks
Higher than 85% of US stocks
Higher than 54% of US stocks
Higher than 49% of US stocks
Higher than 82% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ImmuCell Corp. has a market value of $98.0M and an enterprise value of $90.8M.
Revenue in the twelve months to 30 June 2026: $30.7M. The latest quarter grew 11.5% year on year.
Net income over the same four quarters: $787K, a 2.6% net margin.
Diluted earnings per share, trailing twelve months: $0.08.
Free cash flow in the twelve months to 30 June 2026: $4.2M.
Trailing P/E: 154.1×; forward P/E: −98.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
ImmuCell Corp. employs 73 people — $420K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ImmuCell Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ImmuCell announced preliminary, unaudited third-quarter 2026 product sales results, reporting a 46% increase in product sales.
Why it matters — The reported sales increase offers ICCC watchers an update on the company's recent product sales performance, though the results are preliminary and unaudited.
In its 2026 semi-annual portfolio update, SRK Capital highlighted ImmuCell's strong first quarter of 2026, underscoring the earnings power and cash-flow potential of its core First Defense franchise following the company's strategic exit from Re-Tain.
Why it matters — The update signals to ImmuCell watchers that the company's core First Defense business is performing strongly after its strategic divestiture from Re-Tain.
ImmuCell Corp.'s stock fell 8.8% after reporting Q2 results in which sales rose 11.5% year over year but margins contracted. A $2-million legal settlement boosted profit, and the company is planning a capacity expansion.
Why it matters — ICCC watchers would care because the revenue growth is offset by margin contraction, and the profit was aided by a one-time legal settlement while the company prepares for a capacity expansion.
This item is the transcript of ImmuCell Corporation's Q2 2026 earnings call, published by Seeking Alpha. It presents the company's second-quarter earnings discussion in its own words.
Why it matters — An ICCC watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly financial results and management commentary.
ImmuCell reported higher second-quarter sales and earnings, driven by increased domestic demand for its calf scours prevention products. The company also outlined plans to invest roughly $8 million to more than triple manufacturing capacity by the end of 2027.
Why it matters — For an ImmuCell watcher, the reported sales and earnings gains along with the announced capacity expansion signal ongoing product demand and preparation for greater manufacturing output in the coming years.
As at 12 Oct 2026, ImmuCell Corp. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
No analyst covering ImmuCell Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICCC are extrapolating price history, which says nothing about the business.
ImmuCell Corp. returned +64.0% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
ImmuCell Corporation is an animal health biologics company focused on products that support calf health and cattle productivity. The company develops, manufactures, and markets the First Defense product line, which is designed to help protect newborn calves against scours, a major cause of early-life illness in dairy and beef operations.
The most recent item we track (GlobeNewsWire, 12 Oct 2026): "ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results". ImmuCell announced preliminary, unaudited third-quarter 2026 product sales results, reporting a 46% increase in product sales.
ImmuCell Corporation is an animal health biologics company focused on products that support calf health and cattle productivity. The company develops, manufactures, and markets the First Defense product line, which is designed to help protect newborn calves against scours, a major cause of early-life illness in dairy and beef operations. ImmuCell also offers mastitis-related diagnostic products, including cow-side testing tools used to identify elevated somatic cell counts and help detect mastitis in dairy herds. Its current business is centered on practical, science-based solutions for livestock producers in the dairy and beef industries, with an emphasis on improving animal survivability, health, and day-to-day herd management. Headquartered in Portland, Maine, ImmuCell serves a specialized niche in the animal-health market through biologics, immunological products, and diagnostic assays.
CEO Mr. Paul F. Olivier Te Boekhorst · 73 employees · United States · https://immucell.com
